224 related articles for article (PubMed ID: 8874340)
1. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
4. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
[TBL] [Abstract][Full Text] [Related]
5. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Pectasides D; Samantas E; Fountzilas G; Briasoulis E; Kosmidis P; Skarlos D; Dimopoulos MA; Kalofonos HP; Economopoulos T; Syrigos K
Lung Cancer; 2007 Dec; 58(3):355-61. PubMed ID: 17698241
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
10. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
[TBL] [Abstract][Full Text] [Related]
12. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
13. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
14. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Creemers GJ; Bolis G; Gore M; Scarfone G; Lacave AJ; Guastalla JP; Despax R; Favalli G; Kreinberg R; Van Belle S; Hudson I; Verweij J; Ten Bokkel Huinink WW
J Clin Oncol; 1996 Dec; 14(12):3056-61. PubMed ID: 8955650
[TBL] [Abstract][Full Text] [Related]
15. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
[TBL] [Abstract][Full Text] [Related]
16. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.
Mavroudis D; Pavlakou G; Blazoyiannakis G; Veslemes M; Apostolopoulou F; Kouroussis Ch; Kakolyris S; Agelaki S; Androulakis N; Vardakis N; Magkanas E; Samonis G; Georgoulias V
Lung Cancer; 2003 Jan; 39(1):71-6. PubMed ID: 12499097
[TBL] [Abstract][Full Text] [Related]
17. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Kudelka AP; Tresukosol D; Edwards CL; Freedman RS; Levenback C; Chantarawiroj P; Gonzalez de Leon C; Kim EE; Madden T; Wallin B; Hord M; Verschraegen C; Raber M; Kavanagh JJ
J Clin Oncol; 1996 May; 14(5):1552-7. PubMed ID: 8622071
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
